CDSCO calls Stakeholder meeting for feedback on Sugam, check out details

Published On 2017-07-16 06:36 GMT   |   Update On 2017-07-16 06:36 GMT

Through a recent notice CDSCO have invited stakeholders for meeting regarding the feedback on new modules of SUGAM portal which will be held at FDA Bhawan on respective dates.


The notice states that CDSCO has initiated a comprehensive e-Governance program for filing online applications through SUGAM portal. Several modules has been developed and made live. Now the modules mentioned below have been developed and it has been decided that the views of the stakeholders are taken before the applications are made live.


Therefore,stakeholders have been requested to nominate representatives for meeting on the below mentioned dates to view the demo and give your valuable feedback.




































S.NoProcessDate of stakeholders meeting
1.Granting of NOC & registration of drugs meant for export.17th July 2017, 11:00
2.Grant & Renewal of Blood Bank and CLAA workflow20th July 2017, 11:00
3.COPP Certificate20th July 2017, 15:00
4.Online Process for New Drugs, Fixed Dose Combinations, Subsequent New Drugs.25th July 2017, 11:00
5.CT post Approvals & SAE Reporting24th July 2017, 11:00

The meeting will be held at Conference room, 1st floor, FDA Bhawan, Kotla Road, New Delhi-110002.


Details of the nominees shall be sent to it-helpdesk@cdsco.nic.in


Below is the attachment for the same.


http://www.cdsco.nic.in/writereaddata/meetingnotice12_7_2017.pdf

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News